Targets › SLCX1
1 program from 1 company in 1 trial: 1 Phase 2; Other; next expected readout Nov 2026.
Open in Phaseline: the race on SLCX1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Neurodawn Pharmaceutical | Y-4 combination of pregabalin (GABA analog) and riluzole (glutamate release inhibitor) | GABRA1, SLCX1 | Phase 2 | Postherpetic Neuralgia | Nov 2026 |
Postherpetic Neuralgia (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.